Skip to main content

Table 8 Nitric oxide scavenging activity of eugenol derivatives

From: Lead optimization for promising monoamine oxidase inhibitor from eugenol for the treatment of neurological disorder: synthesis and in silico based study

Compound/sample

IC50 (µg/mL)a

Sr. no

IC50 (µg/mL)a

5a

7.156 ± 0.002

13a

20.23 ± 0.073

5b

6.456 ± 0.023

13b

11.74 ± 0.523

7

9.142 ± 0.061

13c

14.63 ± 0.412

9a

9.007 ± 0.014

13d

11.23 ± 0.032

9b

8.095 ± 0.018

16

18.63 ± 0.654

11

10.71 ± 0.743

17

25.61 ± 0.076

Eugenol

11.724 ± 0.003

l-Ascorbic acid

7.523 ± 0.005

  1. aValue are expressed as mean ± SEM, n = 3
Back to article page

BMC Chemistry

ISSN: 2661-801X

Contact us